Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
FAJARDO, Puerto Rico and EAST WINDSOR, N.J., Nov. 1
/PRNewswire-FirstCall/ -- Warner Chilcott Company, Inc. (a subsidiary of
Warner Chilcott, Ltd., [Nasdaq: WCRX]) and NexMed, Inc. (Nasdaq: NEXM ),
announced today that the two companies have entered into a licensing
agreement granting Warner ...
Beacon Equity Researches: Sanofi-Aventis, Amazon, Yahoo, Johnson & Johnson, Novavax and NexMed
DALLAS, July 1 /PRNewswire/ -- Investment opinion and research leader BeaconEquity.com announces the availability of stock alerts on leading, active stocks in today's news. Each stock alert highlights recent news, trading activity, technical analysis and relevant market research you need to kn...
Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
...administered product for the treatment of erectile dysfunction ("ED"). Also included in the quarter ended March 31, 2009 was a $2.5 million payment to nexmed
Inc. in connection with our acquisition of the rights to its topically applied alprostadil cream for the treatment of ED. Excluding the $11.5 million ...
Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008
...uary 2009, the Company acquired the U.S. rights to nexmed
Inc.'s ("NexMed") topically applied alprostadil cr...previous license agreement between the Company and nexmed
relating to the product was terminated. The Company paid nexmed
an upfront fee of $2.5 million, which will be incl...
Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
...t, we obtained the exclusive
U.S. rights to develop and market NexMed's topically applied alprostadil
cream for the treatment of erectile dysfunction. nexmed
submitted an NDA
with the FDA on September 21, 2007 and is awaiting confirmation of
acceptance of its submission. We paid an upfront fee of $0.5 milli...